Literature DB >> 20413568

EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.

Seza Ozen1, Angela Pistorio, Silvia M Iusan, Aysin Bakkaloglu, Troels Herlin, Riva Brik, Antonella Buoncompagni, Calin Lazar, Ilmay Bilge, Yosef Uziel, Donato Rigante, Luca Cantarini, Maria Odete Hilario, Clovis A Silva, Mauricio Alegria, Ximena Norambuena, Alexandre Belot, Yackov Berkun, Amparo Ibanez Estrella, Alma Nunzia Olivieri, Maria Giannina Alpigiani, Ingrida Rumba, Flavio Sztajnbok, Lana Tambic-Bukovac, Luciana Breda, Sulaiman Al-Mayouf, Dimitrina Mihaylova, Vyacheslav Chasnyk, Claudia Sengler, Maria Klein-Gitelman, Djamal Djeddi, Laura Nuno, Chris Pruunsild, Jurgen Brunner, Anuela Kondi, Karaman Pagava, Silvia Pederzoli, Alberto Martini, Nicolino Ruperto.   

Abstract

OBJECTIVES: To validate the previously proposed classification criteria for Henoch-Schönlein purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) and c-Takayasu arteritis (c-TA).
METHODS: Step 1: retrospective/prospective web-data collection for children with HSP, c-PAN, c-WG and c-TA with age at diagnosis <or=18 years. Step 2: blinded classification by consensus panel of a representative sample of 280 cases. Step 3: statistical (sensitivity, specificity, area under the curve and kappa-agreement) and nominal group technique consensus evaluations.
RESULTS: 827 patients with HSP, 150 with c-PAN, 60 with c-WG, 87 with c-TA and 52 with c-other were compared with each other. A patient was classified as HSP in the presence of purpura or petechiae (mandatory) with lower limb predominance plus one of four criteria: (1) abdominal pain; (2) histopathology (IgA); (3) arthritis or arthralgia; (4) renal involvement. Classification of c-PAN required a systemic inflammatory disease with evidence of necrotising vasculitis OR angiographic abnormalities of medium-/small-sized arteries (mandatory criterion) plus one of five criteria: (1) skin involvement; (2) myalgia/muscle tenderness; (3) hypertension; (4) peripheral neuropathy; (5) renal involvement. Classification of c-WG required three of six criteria: (1) histopathological evidence of granulomatous inflammation; (2) upper airway involvement; (3) laryngo-tracheo-bronchial involvement; (4) pulmonary involvement (x-ray/CT); (5) antineutrophilic cytoplasmic antibody positivity; (6) renal involvement. Classification of c-TA required typical angiographic abnormalities of the aorta or its main branches and pulmonary arteries (mandatory criterion) plus one of five criteria: (1) pulse deficit or claudication; (2) blood pressure discrepancy in any limb; (3) bruits; (4) hypertension; (5) elevated acute phase reactant.
CONCLUSION: European League Against Rheumatism/Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology European Society propose validated classification criteria for HSP, c-PAN, c-WG and c-TA with high sensitivity/specificity.

Entities:  

Mesh:

Year:  2010        PMID: 20413568     DOI: 10.1136/ard.2009.116657

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  301 in total

1.  [Polyarteritis nodosa: differential diagnostics and therapy].

Authors:  J H Schirmer; K Holl-Ulrich; F Moosig
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

Review 2.  Pediatric vasculitis.

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 3.  Renovascular hypertension--is it fibromuscular dysplasia or Takayasu arteritis.

Authors:  Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2012-03-28       Impact factor: 3.714

4.  Atypical tumour-like involvement of the colon in Henoch-Schonlein purpura successfully treated with the administration of factor XIII.

Authors:  Katuyoshi Ando; Mikihiro Fujiya; Ryuji Sugiyama; Toshie Nata; Yoshiki Nomura; Nobuhiro Ueno; Shin Kashima; Chisato Ishikawa; Yuhei Inaba; Takahiro Ito; Kentaro Moriichi; Kotaro Okamoto; Katsuya Ikuta; Jiro Watari; Yusuke Mizukami; Yutaka Kohgo
Journal:  BMJ Case Rep       Date:  2011-05-12

Review 5.  Taxonomy for systemic lupus erythematosus with onset before adulthood.

Authors:  Clovis A Silva; Tadej Avcin; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

Review 6.  Tuberculosis and Takayasu arteritis: case-based review.

Authors:  Moritz K Jansson; Hilte F Geerdes-Fenge; Antje Kangowski; Christian Kneitz; Emil C Reisinger
Journal:  Rheumatol Int       Date:  2019-01-03       Impact factor: 2.631

7.  Clinical and histopathological prognostic factors affecting the renal outcomes in childhood ANCA-associated vasculitis.

Authors:  Gül Özçelik; Hafize Emine Sönmez; Sezgin Şahin; Ayşim Özağarı; Meral Torun Bayram; Rümeysa Yasemin Çiçek; Evrim Kargın Çakıcı; Elif Çomak; Kenan Barut; Nihal Şahin; Sevcan Bakkaloğlu; İbrahim Gökçe; Ali Düzova; Yelda Bilginer; Ceyhun Açarı; Engin Melek; Beltinge Demircioğlu Kılıç; Semanur Özdel; Amra Adroviç; Özgür Kasapçopur; Erbil Ünsal; Harika Alpay; Diclehan Orhan; Rezan Topaloğlu; Ruhan Düşünsel; Seza Özen
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

8.  Comparison between adults and children with Henoch-Schönlein purpura nephritis.

Authors:  Shan Lu; Dong Liu; Jing Xiao; Wenming Yuan; Xiaoyang Wang; Xiaoxue Zhang; Jin Zhang; Zhangsuo Liu; Zhanzheng Zhao
Journal:  Pediatr Nephrol       Date:  2014-12-07       Impact factor: 3.714

Review 9.  Vasculitis: do we know more to classify better?

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

10.  Clinical significance of ANCA positivity in patients with IgA vasculitis: a retrospective monocentric study.

Authors:  Jae Yeon Kim; Hyeok Choi; Minyoung Kevin Kim; Soo Bin Lee; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2019-08-01       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.